Menglan Wang

Zhejiang Provincial Key Laboratory Of Anti Cancer Chinese Medicines And Natural Medicines
Hangzhou, 311121, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Elemene Augments the Effects of Anti-PD-1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR-130a-5p/SPP/MHC-I Axis.

Elemene Augments the Effects of Anti-PD-1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR-130a-5p/SPP/MHC-I Axis.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 03, 2025

Folate Receptor-Targeted Liposomes Loaded with Actinomycin X2 Enhance Antitumor Potency for HCCLM3 Hepatocellular Carcinoma Both In Vitro and In Vivo.

Folate Receptor-Targeted Liposomes Loaded with Actinomycin X2 Enhance Antitumor Potency for HCCLM3 Hepatocellular Carcinoma Both In Vitro and In Vivo.

Journal: Molecular pharmaceutics

Published: June 09, 2025

mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.

mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.

Journal: MedComm

Published: March 29, 2025

The upregulation of GDF15 is controlled epigenetically by oncogenic TCF19 signaling in human hepatocellular carcinoma.

The upregulation of GDF15 is controlled epigenetically by oncogenic TCF19 signaling in human hepatocellular carcinoma.

Journal: iScience

Published: January 24, 2025

Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma.

Redistribution of super-enhancers promotes malignancy in human hepatocellular carcinoma.

Journal: Journal of advanced research

Published: September 14, 2024

Development of a bacteria-nanosapper for the active delivery of ZIF-8 particles containing therapeutic genes for cancer immune therapy.

Development of a bacteria-nanosapper for the active delivery of ZIF-8 particles containing therapeutic genes for cancer immune therapy.

Journal: Acta pharmaceutica Sinica. B

Published: May 17, 2024

Intron Retention of DDX39A Driven by SNRPD2 is a Crucial Splicing Axis for Oncogenic MYC/Spliceosome Program in Hepatocellular Carcinoma.

Intron Retention of DDX39A Driven by SNRPD2 is a Crucial Splicing Axis for Oncogenic MYC/Spliceosome Program in Hepatocellular Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 01, 2024

Establishment and characterization of a highly metastatic hepatocellular carcinoma cell line.

Establishment and characterization of a highly metastatic hepatocellular carcinoma cell line.

Journal: Bioengineered

Published: January 07, 2024

Kinesin family member 18B activates mTORC1 signaling via actin gamma 1 to promote the recurrence of human hepatocellular carcinoma.

Kinesin family member 18B activates mTORC1 signaling via actin gamma 1 to promote the recurrence of human hepatocellular carcinoma.

Journal: Oncogenesis

Published: February 20, 2023

The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma.

The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma.

Journal: Nature communications

Published: February 22, 2021

USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1.

USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1.

Journal: Cell death & disease

Published: February 19, 2021

Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.

Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.

Journal: Cancer science

Published: December 09, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026